253 related articles for article (PubMed ID: 20145158)
21. Secreted clusterin gene silencing enhances chemosensitivity of a549 cells to cisplatin through AKT and ERK1/2 pathways in vitro.
Zhang B; Zhang K; Liu Z; Hao F; Wang M; Li X; Yin Z; Liang H
Cell Physiol Biochem; 2014; 33(4):1162-75. PubMed ID: 24751980
[TBL] [Abstract][Full Text] [Related]
22. Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer.
Al-Asaaed S; Winquist E
Curr Oncol Rep; 2013 Apr; 15(2):113-8. PubMed ID: 23266703
[TBL] [Abstract][Full Text] [Related]
23. sCLU as prognostic biomarker and therapeutic target in osteosarcoma.
Ma J; Gao W; Gao J
Bioengineered; 2019 Dec; 10(1):229-239. PubMed ID: 31117872
[TBL] [Abstract][Full Text] [Related]
24. Silencing of secretory clusterin sensitizes NSCLC cells to V-ATPase inhibitors by downregulating survivin.
Kim YS; Jin HO; Hong SE; Song JY; Hwang CS; Park IC
Biochem Biophys Res Commun; 2018 Jan; 495(2):2004-2009. PubMed ID: 29253572
[TBL] [Abstract][Full Text] [Related]
25. Clusterin, a Novel DEC1 Target, Modulates DNA Damage-Mediated Cell Death.
Ming X; Bao C; Hong T; Yang Y; Chen X; Jung YS; Qian Y
Mol Cancer Res; 2018 Nov; 16(11):1641-1651. PubMed ID: 30002194
[TBL] [Abstract][Full Text] [Related]
26. Secreted clusterin (sCLU) regulates cell proliferation and chemosensitivity to cisplatin by modulating ERK1/2 signals in human osteosarcoma cells.
Huang H; Wang L; Li M; Wang X; Zhang L
World J Surg Oncol; 2014 Aug; 12():255. PubMed ID: 25106434
[TBL] [Abstract][Full Text] [Related]
27. Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.
Tang Y; Liu F; Zheng C; Sun S; Jiang Y
J Exp Clin Cancer Res; 2012 Sep; 31(1):73. PubMed ID: 22967941
[TBL] [Abstract][Full Text] [Related]
28. Clusterin silencing inhibits proliferation and reduces invasion in human laryngeal squamous carcinoma cells.
Wang Q; Cao W; Su Q; Liu Z; Zhang L
World J Surg Oncol; 2014 Apr; 12():124. PubMed ID: 24767179
[TBL] [Abstract][Full Text] [Related]
29. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
30. siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human non-small cell lung cancer xenografts in immunodeficient mice.
Zhang B; Liu ZM; Hao FG; Wang M
Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1595-601. PubMed ID: 24943969
[TBL] [Abstract][Full Text] [Related]
31. sCLU regulates cisplatin chemosensitivity of lung cancer cells in vivo.
Ma G; Cai H; Gao L; Wang M; Wang H
World J Surg Oncol; 2015 Feb; 13():80. PubMed ID: 25884382
[TBL] [Abstract][Full Text] [Related]
32. Glyceryl trinitrate‑induced cytotoxicity of docetaxel‑resistant prostatic cancer cells is associated with differential regulation of clusterin.
Bouaouiche S; Magadoux L; Dondaine L; Reveneau S; Isambert N; Bettaieb A; Jeannin JF; Laurens V; Plenchette S
Int J Oncol; 2019 Apr; 54(4):1446-1456. PubMed ID: 30720069
[TBL] [Abstract][Full Text] [Related]
33. Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting clusterin improves response to paclitaxel.
Hassan MK; Watari H; Han Y; Mitamura T; Hosaka M; Wang L; Tanaka S; Sakuragi N
J Exp Clin Cancer Res; 2011 Dec; 30(1):113. PubMed ID: 22185350
[TBL] [Abstract][Full Text] [Related]
34. Small interfering RNA targeted to secretory clusterin blocks tumor growth, motility, and invasion in breast cancer.
Niu Z; Li X; Hu B; Li R; Wang L; Wu L; Wang X
Acta Biochim Biophys Sin (Shanghai); 2012 Dec; 44(12):991-8. PubMed ID: 23099883
[TBL] [Abstract][Full Text] [Related]
35. Repression of IR-inducible clusterin expression by the p53 tumor suppressor protein.
Criswell T; Klokov D; Beman M; Lavik JP; Boothman DA
Cancer Biol Ther; 2003; 2(4):372-80. PubMed ID: 14508108
[TBL] [Abstract][Full Text] [Related]
36. The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target.
Muhammad LA; Saad F
Expert Rev Anticancer Ther; 2015; 15(9):1049-61. PubMed ID: 26313417
[TBL] [Abstract][Full Text] [Related]
37. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
Miyake H; Hara I; Gleave ME
Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
[TBL] [Abstract][Full Text] [Related]
38. Low dose IR-induced IGF-1-sCLU expression: a p53-repressed expression cascade that interferes with TGFβ1 signaling to confer a pro-survival bystander effect.
Klokov D; Leskov K; Araki S; Zou Y; Goetz EM; Luo X; Willson D; Boothman DA
Oncogene; 2013 Jan; 32(4):479-90. PubMed ID: 22391565
[TBL] [Abstract][Full Text] [Related]
39. Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.
Matsumoto H; Yamamoto Y; Shiota M; Kuruma H; Beraldi E; Matsuyama H; Zoubeidi A; Gleave M
Cancer Res; 2013 Aug; 73(16):5206-17. PubMed ID: 23786771
[TBL] [Abstract][Full Text] [Related]
40. IR-inducible clusterin gene expression: a protein with potential roles in ionizing radiation-induced adaptive responses, genomic instability, and bystander effects.
Klokov D; Criswell T; Leskov KS; Araki S; Mayo L; Boothman DA
Mutat Res; 2004 Dec; 568(1):97-110. PubMed ID: 15530543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
